DexCom Inc. (NASDAQ:DXCM) is one of the best medical technology stocks to invest in. On February 12, DexCom Inc. (NASDAQ:DXCM) shared its Q4 2025 earnings and reported $1.26 billion in quarterly ...

Dexcom reports 13% Q4 revenue growth to $1.26B, beating analyst expectations despite mixed analyst ratings and competitive pressures.

DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus ...

New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

Q4 2025 Management View Jacob Leach, President, CEO & Director, marked his first call as CEO by outlining three strategic priorities: "We will be the premier glucose sensing solution for all," ...

Stelo by Dexcom is a wearable glucose biosensor that brings continuous glucose monitoring into the consumer wellness space, aimed at adults who are not using insulin but still want detailed glucose ...

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

Patients with type 2 diabetes demonstrated improved glycemic control with the use of automated insulin delivery regardless of baseline C-peptide levels. Automated insulin delivery (AID) systems should ...

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...

Two experts discuss why more research is needed before continuous glucose monitors can be used reliably for insulin management for critically ill patients. “Continuous glucose monitors show promise ...

Introduction Postbariatric hypoglycaemia (PBH) is a complex medical condition with a significant impact on patients’ quality of life. The underlying mechanisms remain to be elucidated. We have shown ...